129 related articles for article (PubMed ID: 15341955)
21. The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.
Levin JI; DiJoseph JF; Killar LM; Sharr MA; Skotnicki JS; Patel DV; Xiao XY; Shi L; Navre M; Campbell DA
Bioorg Med Chem Lett; 1998 May; 8(10):1163-8. PubMed ID: 9871728
[TBL] [Abstract][Full Text] [Related]
22. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
23. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.
Wada CK
Curr Top Med Chem; 2004; 4(12):1255-67. PubMed ID: 15320725
[TBL] [Abstract][Full Text] [Related]
24. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).
Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583
[TBL] [Abstract][Full Text] [Related]
25. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
[TBL] [Abstract][Full Text] [Related]
26. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
27. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
28. Irreversible inhibition of zinc-containing protease by oxazolidinone derivatives. Novel inactivation chemistry.
Kim DH; Chung SJ; Kim EJ; Tian GR
Bioorg Med Chem Lett; 1998 Apr; 8(7):859-64. PubMed ID: 9871555
[TBL] [Abstract][Full Text] [Related]
29. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
30. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties.
Santos MA; Marques S; Gil M; Tegoni M; Scozzafava A; Supuran CT
J Enzyme Inhib Med Chem; 2003 Jun; 18(3):233-42. PubMed ID: 14506914
[TBL] [Abstract][Full Text] [Related]
31. An alternative synthesis of peptidyl alpha-keto-2-oxazolines.
Dunn D; Chatterjee S
Bioorg Med Chem Lett; 1998 May; 8(10):1273-6. PubMed ID: 9871748
[TBL] [Abstract][Full Text] [Related]
32. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2004 Nov; 11(22):2911-77. PubMed ID: 15544483
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
[TBL] [Abstract][Full Text] [Related]
34. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P; Devel L; Makaritis A; Beau F; Georgiadis D; Matziari M; Yiotakis A; Dive V
Biochimie; 2005; 87(3-4):393-402. PubMed ID: 15781327
[TBL] [Abstract][Full Text] [Related]
35. In silico study of MMP inhibition.
Rouffet M; Denhez C; Bourguet E; Bohr F; Guillaume D
Org Biomol Chem; 2009 Sep; 7(18):3817-25. PubMed ID: 19707688
[TBL] [Abstract][Full Text] [Related]
36. Difluoroketones as inhibitors of matrix metalloprotease-13.
Reiter LA; Martinelli GJ; Reeves LA; Mitchell PG
Bioorg Med Chem Lett; 2000 Jul; 10(14):1581-4. PubMed ID: 10915056
[TBL] [Abstract][Full Text] [Related]
37. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.
Devel L; Czarny B; Beau F; Georgiadis D; Stura E; Dive V
Biochimie; 2010 Nov; 92(11):1501-8. PubMed ID: 20696203
[TBL] [Abstract][Full Text] [Related]
38. Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.
Moriyama H; Tsukida T; Inoue Y; Kondo H; Yoshino K; Nishimura S
Bioorg Med Chem Lett; 2003 Aug; 13(16):2737-40. PubMed ID: 12873504
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
40. Advances in matrix metalloproteinase inhibitors based on pyrrolidine scaffold.
Cheng XC; Wang Q; Fang H; Xu WF
Curr Med Chem; 2008; 15(4):374-85. PubMed ID: 18288992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
